Summary

The administration of recombinant activated factor VII (rFVIIa)by continuous infusion has provided a safe and convenient alternativeto bolus injections in haemophiliacs with inhibitors, but ithas only been reported in a single case with congenital factorVII(FVII) deficiency. The results of 12 consecutive surgicalprocedures in 7 patients with congenital FVII deficiency are reportedhere. rFVIIa was always given in continuous infusion, aiming at plasma FVII activity of 0.5 IU/mL.Treatment was given for2 to 7 days with a mean total dose of 7.8 mg rFVIIa. Blood losswas as expected from the different types of procedures and theonly thromboembolic complication was a superficial thrombophlebitisat the infusion site. This mode of substitution wastherefore safe, effective and well tolerated.